Eyenovia, Inc. — FY2020 Form 10-K
Filing identity: The supplied filing is Eyenovia, Inc. (Nasdaq: EYEN), not HYPERION DEFI, INC. It covers the fiscal year ended December 31, 2020; the “2020 Q4” label is not the reporting period of this annual report. Filed March 30, 2021.
Business context
Eyenovia is a clinical-stage ophthalmic company developing drug candidates using its Optejet microdose delivery platform. Its pipeline targets presbyopia (MicroLine), pediatric progressive myopia (MicroPine), and pupil dilation (MydCombi, also called MicroStat). The company had not generated product-sales revenue or obtained marketing approval by year-end.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $2.0 million | None |
| Cost of revenue / gross profit | $0.8 million / $1.2 million | None / none |
| Research and development expense | $13.3 million | $14.1 million |
| General and administrative expense | $7.7 million | $7.2 million |
| Net loss | $19.8 million | $21.2 million |
| Net loss per share, basic and diluted | $0.94 | $1.47 |
| Cash used in operating activities | $6.4 million | $18.9 million |
| Cash and cash equivalents at year-end | $28.4 million | $14.2 million |
| Working capital at year-end | $15.2 million | Not stated in the supplied text |
| Total debt at year-end | $0.5 million | None reported |
FY2020 revenue was a $2.0 million Arctic Vision milestone; the $4.0 million Arctic Vision and $10.0 million Bausch upfront payments remained deferred at year-end, as did $1.6 million of related license costs payable to Senju. Accordingly, recognized revenue does not represent product sales. Gross profit was $1.2 million, but a product-sales margin is not meaningful at this stage.
Operating cash use improved from 2019, while year-end cash rose mainly through financing: net cash from financing activities was $20.9 million, including public-offering and private-placement proceeds, warrant exercises, and a $0.5 million PPP loan. The auditor included a going-concern explanatory paragraph: management and the auditor said existing cash was not sufficient to support operations for at least one year from issuance without additional funding. The filing states substantial doubt exists about continuing as a going concern.
Changes, outlook, and material developments
- Net loss narrowed by about $1.4 million year over year. R&D expense fell 6%, mainly due to partner cost reimbursements and reduced activity amid COVID-19; G&A rose 7%, including higher patent and business-development legal costs.
- In 2020, Eyenovia received $10.0 million upfront from Bausch Health for MicroPine rights in the United States and Canada, with up to $35.0 million in potential additional milestone payments and tiered royalties. Bausch assumed oversight and costs of the CHAPERONE study.
- Arctic Vision received rights to develop and commercialize MicroPine and MicroLine in Greater China and South Korea. Eyenovia received $4.0 million upfront, may receive up to $41.75 million in additional payments, and owes Senju a share of certain proceeds. One $2.0 million milestone was recognized in 2020.
- MIST-1 and MIST-2 Phase III studies of MydCombi reported positive results. The company submitted its NDA in December 2020; the FDA accepted it in March 2021, with a stated PDUFA date of October 28, 2021.
- MicroLine’s first Phase III VISION trial began in December 2020; the filing projected VISION-1 topline results in Q2 2021. MicroPine’s CHAPERONE enrollment had resumed after COVID-related delays; full enrollment was expected in Q4 2021.
- Management expected R&D and G&A spending to increase. No specific financial guidance or forecast for revenue, earnings, cash runway, or cash burn is provided.
- COVID-19 had delayed MicroPine trial enrollment and initiation, although enrollment resumed. The company also cited clinical, regulatory, financing, commercialization, manufacturing, competition, intellectual-property, and partner-execution risks.
Key facts for investors to verify
- Confirm the issuer: the filing is Eyenovia, Inc., while the request metadata names HYPERION DEFI, INC.
- Review the latest cash position, financing completed after March 30, 2021, and management’s current assessment of going-concern risk.
- Check the FDA’s MydCombi NDA decision and any subsequent regulatory or launch developments; the PDUFA date is a filing-era expectation, not an approval.
- Track MicroLine and MicroPine trial progress, enrollment, results, and any COVID-related or other delays.
- Verify license-payment conditions, the accounting for deferred upfront fees, Senju’s share of Arctic Vision proceeds, and whether potential milestones or royalties have been earned.